Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis.
Melioidosis, caused by the intracellular pathogen Burkholderia pseudomallei, is endemic in northern Australia and Southeast Asia. Risk factors for this infection have also been associated with functional neutrophil defects. Because of this, granulocyte colony-stimulating factor (G-CSF) was adopted for use in patients with septic shock due to melioidosis in December 1998. We compared the mortality rates from before and after the introduction of G-CSF therapy at the Royal Darwin Hospital (Darwin, Australia) during the period of 1989-2002. The mortality rate decreased from 95% to 10% after the introduction of G-CSF. Risk factors, the duration of illness before presentation, and the severity of illness were similar in both groups. A smaller decrease in mortality among patients in the intensive care unit who did not have melioidosis was observed, suggesting that other changes in management did not account for the magnitude of the benefit seen. We conclude that G-CSF may have contributed to the reduction in the mortality rate among patients with septic shock due to melioidosis.
Cheng
Allen C
AC
Menzies School of Health Research, Royal Darwin Hospital, Northern Territory Clinical School, Flinders University, Casuarina NT, Darwin, Australia. allenc@menzies.edu.au
Stephens
Dianne P
DP
Anstey
Nicholas M
NM
Currie
Bart J
BJ
D000293:Adolescent; D000328:Adult; D016957:Burkholderia pseudomallei; D002648:Child; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008554:Melioidosis / Q000188:drug therapy* / Q000401:mortality; D000077731:Meropenem; D008875:Middle Aged; D012772:Shock, Septic / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D013845:Thienamycins / Q000627:therapeutic use
D013845:Thienamycins; D016179:Granulocyte Colony-Stimulating Factor; D000077731:Meropenem